Market revenue in 2022 | USD 241.5 million |
Market revenue in 2030 | USD 475.1 million |
Growth rate | 8.8% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.26% in 2022. Horizon Databook has segmented the China thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
The key factors driving this market include the increasing prevalence of cardiovascular diseases, the rising geriatric population, and the growing prevalence of diseases such as DVT & PE. For instance, according to a report by the National Library of Medicine, an estimated 330 million people suffered from CVDs in China in 2019 and related deaths accounted for 46.7% of rural & 44.2% of urban populations.
Biomarkers are expected to increase the Likelihood of Approval (LOA) of clinical studies. According to an analysis by Biomedtracker, out of 9,985 phase transitions, 512 were identified that incorporated a selection biomarker for patient stratification.
The use of selection biomarkers raises the LOA of Phase I from 10% to 25%. Most biomarker tests in China are not reimbursable, and patients have to pay out of their pockets for such tests. This factor can often prove to be restrictive to the growth of the thrombosis and hemostasis biomarkers market.
Horizon Databook provides a detailed overview of country-level data and insights on the China thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into China thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account